StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
Publishing Date
2023 - 10 - 15
1
2023 - 09 - 12
1
2023 - 07 - 26
1
2023 - 03 - 23
1
2023 - 03 - 18
1
2022 - 11 - 23
1
2022 - 10 - 31
2
2022 - 09 - 19
1
2022 - 09 - 10
1
2022 - 06 - 20
1
2022 - 06 - 17
1
2022 - 05 - 27
1
2022 - 02 - 02
1
2022 - 01 - 24
1
2022 - 01 - 21
1
Sector
Health technology
16
Tags
Abbvie
78
Active
14
Aesthetic
22
Alliances
19
America
43
Antibody
17
Application
15
Approval
37
Atopic dermatitis
10
Biomidwest
43
Biotech-beach
10
Business
12
Cancer
53
Cd20
13
Clinical-trials-phase-iii
26
Collaboration
23
Conference
32
Contract
13
Deadline
11
Dermatitis
14
Disease
65
Drug
75
Duobody
13
Earnings
22
Europe
16
Events
24
Expected
18
Eye
17
Fda
42
Financial
26
Financial results
12
Genetown
11
Global
113
Growing
24
Growth
174
Health
20
Key
12
Leukemia
16
Market
388
Meeting
13
Migraine
23
N/a
789
Pharma
18
Pharmaceuticals
11
Phase 3
30
Positive
31
Reach
16
Report
97
Research
81
Results
80
Rinvoq
28
Risankizumab
14
Set
20
Skyrizi
16
Therapeutics
88
Therapy
40
Treatment
117
Trial
32
Ulcerative colitis
14
Year
12
Entities
Abbvie inc.
16
Symbols
ABBV
16
JNJ
2
Exchanges
Nyse
16
Crawled Date
2023 - 10 - 15
1
2023 - 09 - 12
1
2023 - 07 - 26
1
2023 - 03 - 23
1
2023 - 03 - 18
1
2022 - 11 - 23
1
2022 - 10 - 31
2
2022 - 09 - 19
1
2022 - 09 - 10
1
2022 - 06 - 20
1
2022 - 06 - 17
1
2022 - 05 - 27
1
2022 - 02 - 02
1
2022 - 01 - 24
1
2022 - 01 - 22
1
Crawled Time
00:20
1
08:00
3
08:20
1
12:00
1
12:20
2
13:00
1
14:00
1
14:30
1
15:00
1
16:00
1
16:20
2
21:00
1
Source
www.biospace.com
9
www.prnewswire.com
7
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Skyrizi
symbols :
Abbv
save search
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
Published:
2023-10-15
(Crawled : 16:20)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
skyrizi
disease
study
AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Published:
2023-09-12
(Crawled : 14:30)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
13.75%
|
O:
0.31%
H:
0.07%
C:
-0.15%
skyrizi
disease
study
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
Published:
2023-07-26
(Crawled : 12:00)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
19.04%
|
O:
-0.67%
H:
0.0%
C:
0.0%
skyrizi
psoriasis
study
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Published:
2023-03-23
(Crawled : 15:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
10.33%
|
O:
0.28%
H:
1.56%
C:
0.78%
skyrizi
risankizumab
study
ulcerative colitis
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
Published:
2023-03-18
(Crawled : 16:20)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
il-17
skyrizi
abbvie
psoriasis
response
therapy
results
study
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
Published:
2022-11-23
(Crawled : 08:00)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
6.1%
|
O:
0.1%
H:
0.62%
C:
-0.35%
skyrizi
treatment
disease
active
approval
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
Published:
2022-10-31
(Crawled : 16:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
14.86%
|
O:
-1.65%
H:
1.11%
C:
0.85%
skyrizi
rinvoq
AbbVie Drops Autoimmune Program, Prioritizes Skyrizi and Rinvoq
Published:
2022-10-31
(Crawled : 14:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
14.86%
|
O:
-1.65%
H:
1.11%
C:
0.85%
skyrizi
rinvoq
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published:
2022-09-19
(Crawled : 08:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
17.69%
|
O:
-0.29%
H:
0.15%
C:
-0.68%
skyrizi
treatment
disease
chmp
risankizumab
positive
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
Published:
2022-09-10
(Crawled : 08:20)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
skyrizi
trials
skin
week
100
results
AbbVie's Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn's Disease
Published:
2022-06-20
(Crawled : 12:20)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
il-23
skyrizi
disease
fda
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Published:
2022-06-17
(Crawled : 12:20)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
24.26%
|
O:
1.05%
H:
0.0%
C:
0.0%
il-23
skyrizi
fda
disease
active
approval
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published:
2022-05-27
(Crawled : 08:00)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
11.44%
|
O:
-1.98%
H:
0.0%
C:
0.0%
skyrizi
disease
lancet
risankizumab
results
phase 3
AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff
Published:
2022-02-02
(Crawled : 21:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
23.6%
|
O:
-1.94%
H:
0.0%
C:
0.0%
patent
skyrizi
humira
rinvoq
AbbVie’s SKYRIZI Offers New Option for Psoriatic Arthritis Sufferers
Published:
2022-01-24
(Crawled : 13:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
27.23%
|
O:
-0.33%
H:
0.32%
C:
-0.5%
skyrizi
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
Published:
2022-01-21
(Crawled : 00:20)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
26.17%
|
O:
-0.83%
H:
0.0%
C:
0.0%
skyrizi
fda
risankizumab
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.